Zydus US024
Welcome,         Profile    Billing    Logout  
 0 Trials 
6 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Carney, Carol
NCT06427395: Open-Label Extension Study of Saroglitazar Magnesium in Participants with Primary Biliary Cholangitis

Recruiting
3
150
US, RoW
Saroglitazar Magnesium 1 mg
Zydus Therapeutics Inc.
Primary Biliary Cholangitis
04/27
07/27
EPICS-III, NCT05133336 / 2022-001634-10: Saroglitazar Magnesium for Treatment of Primary Biliary Cholangitis

Active, not recruiting
2/3
186
NA
Saroglitazar Magnesium 1 mg, Saroglitazar Magnesium 2 mg, Placebo
Zydus Therapeutics Inc., Zydus Therapeutics Inc.
Primary Biliary Cholangitis
05/25
05/25
TARGET-HCC, NCT02954094: A Longitudinal Observational Study of the Natural History and Management of Patients With HCC

Recruiting
N/A
10000
Europe, US
Target PharmaSolutions, Inc.
Hepatocellular Cancer
10/25
10/25
TARGET-IBD, NCT03251118: A 5-year Longitudinal Observational Study of Patients Undergoing Therapy for Inflammatory Bowel Disease

Recruiting
N/A
15000
US
Target PharmaSolutions, Inc.
Inflammatory Bowel Diseases, Crohn's Disease, Ulcerative Colitis, Indeterminate Colitis
10/25
10/25
NCT02815891: A Longitudinal Observational Study of Patients With Nonalcoholic Steatohepatitis (NASH) and Related Conditions Across the Entire Spectrum of Nonalcoholic Fatty Liver Disease (NAFLD)

Recruiting
N/A
15000
Europe, US
Target PharmaSolutions, Inc.
Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis
07/36
07/36
Wede, Kory
EPICS-III, NCT05133336 / 2022-001634-10: Saroglitazar Magnesium for Treatment of Primary Biliary Cholangitis

Active, not recruiting
2/3
186
NA
Saroglitazar Magnesium 1 mg, Saroglitazar Magnesium 2 mg, Placebo
Zydus Therapeutics Inc., Zydus Therapeutics Inc.
Primary Biliary Cholangitis
05/25
05/25

Download Options